The European & Developing Countries Clinical Trials Partnership (EDCTP) exists to accelerate the clinical development of new or improved health technologies for the identification, treatment and prevention of poverty-related and neglected infectious diseases, including (re-)emerging diseases.

The Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3) builds on the first and second EDCTP programmes and is a partnership between the EU and the EDCTP Association, whose members are several European and African countries. 

The partnership will deliver new solutions for reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world.

Key figures

• Total budget of Global Health EDCTP3 is 1.6 billon euro
• The partnership includes 40 European & African countries 

Participation Flanders

The following organisations based in Flanders are partner in ongoing EDCTP3 projects (2022 & 2023 work programme):

• University of Antwerp in the projects 'SEMA ReACT', 'SNIP-AFRICA', 'GenPath Africa' & 'PROTECT'
• Institute for Tropical Medicine (ITM) in the project 'STROGHAT'
• Ghent University in the project 'NeuroSolve' & 'ODIN'
• Flemish Institute for Biotechnology (VIB) in the project 'ODIN'
• Janssen Pharmaceutica nv in the project 'CTCAN'

Past & current calls for proposals

Since it took off in 2022, EDCTP has launched several calls of proposals. Information on the latest calls for proposals can be found in the 2025 annual work programme. Any further information can be found on the EDCTP3 Calls for proposals webpage.

Key documents

• Draft partnership proposal (August 2020) 
• Strategic Research and Innovation Agenda of the GH EDCTP3 (January 2022) 
• Policy context: Global health - EDCTP

Contact

Partnership: EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu